行情

PCRX

PCRX

PACIRA制药
NASDAQ

实时行情|Nasdaq Last Sale

42.92
+0.34
+0.80%
盘后: 42.84 -0.08 -0.19% 16:11 11/15 EST
开盘
42.78
昨收
42.58
最高
43.03
最低
42.20
成交量
57.83万
成交额
--
52周最高
50.30
52周最低
34.64
市值
17.91亿
市盈率(TTM)
817.52
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PCRX 新闻

  • Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pay Justified?
  • Simply Wall St..4天前
  • Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference
  • GlobeNewswire.4天前
  • Edited Transcript of PCRX earnings conference call or presentation 7-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.5天前
  • Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
  • Zacks.11/08 16:31

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

PCRX 简况

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
展开

Webull提供Pacira Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。